Evaluation of potential diagnostics, including health economic assessment, for clinical use
Published: 16 January 2018
Glasgow’s unique infrastructure provides physical ‘proximity’, which is driving enhanced working relationships between academic, clinical, pathology, biomedical staff and industry, supporting the translation of tests/diagnostics towards translation and adoption.
Glasgow’s unique infrastructure provides physical ‘proximity’, which is driving enhanced working relationships between academic, clinical, pathology, biomedical staff and industry, supporting the translation of tests/diagnostics towards translation and adoption.
Our NHS and industry partners benefit from access to world-leading academic researchers, facilities, expertise and end-user environments enabling product testing and commercial development. Additionally partners can engage with health economists providing advice and modelling to evaluate the potential economic and/or health benefits of new products for clinical application.
The Node is currently working with its industry and clinical partners and health economists to deliver a number of projects which are evaluating potential diagnostics or the impact of potential changes in clinical practice. These projects include evaluation of a genomic panel for clinical use and evaluation of use of an NGS panel-based assay for cancer stratification by potential pharmaceutical partners. Additionally our health economist is working with partners to generate models to assess value of potential new molecular diagnostics or costs of extending diagnostic testing for cancer.
First published: 16 January 2018